FDA Pushes Risk-Based Patient Selection for Microbial Vector Therapies

Clinical Trials Advisor
The FDA is calling for risk management plans for clinical development of microbial vectors for gene therapy, focusing on the potential for vectors to germinate, regerminate or reseed.

To View This Article:


Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00